Compare AU
Compare ASAO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Abrdn Sust Asian Opportunities Active ETF (ASAO) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ASAO | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 82 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,323.41 |
Average age group | N/A | > 35 |
Key Summary
ASAO | CURE | |
|---|---|---|
Strategy | ASAO.AX was created on 2022-10-17 by abrdn. The fund's investment portfolio concentrates primarily on total market equity. To provide investors with high capital growth over the medium to long term (3-5 years) by seeking exposure to the Asian markets (other than the Japan market), adjusted to take into account certain ESG (Environmental, Social and Governance) considerations. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co Ltd (13.57 %) Tencent Holdings Ltd (7.84 %) Samsung Electncs Co (3.94 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Information Technology (35.19 %) Financials (18.83 %) Communication Services (17.33 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | China (30.35 %) India (23.09 %) Taiwan (21.16 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 1.18 % | 0.45 % |
Key Summary
ASAO | CURE | |
|---|---|---|
Issuer | abrdn | Global X |
Tracking index | MSCI AC Asia ex JP | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 1.18 % | 0.45 % |
Price | $1.155 | $49.94 |
Size | N/A | $38.065 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.84 % | 4.24 % |
Market | ASX | ASX |
First listed date | 18/10/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ASAO | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 82 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,323.41 |
Average age group | N/A | > 35 |
Pros and Cons
ASAO | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ASAO | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |